logo
Officials step up plans to combat flesh-eating screwworm

Officials step up plans to combat flesh-eating screwworm

Yahoo5 hours ago

Texas officials are stepping up their plans to stop the spread of a flesh-eating parasite, [Reuters reports](https://www.reuters.com/world/us/usda-plans-sterile-fly-facility-texas-combat-screwworm-2025-06-18/).
The parasite, known as the New World screwworm (Cochliomyia hominivorax), has triggered a public health emergency in Costa Rica, prompting experts to warn Canadian travellers to take precautions.
State-side, Texas officials said Wednesday they are building a sterile fly dispersal facility. The Department of Agriculture also announced plans for a sterile fly production facility at Moore Air Base, which could take two to three years to construct.
New World screwworm (NWS) was eradicated from the U.S. in 1966, but the current health emergencies in central America and Mexico have seen the parasite moving northward.
On its website, the U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) says it has been partnering with other USDA agencies, including the U.S. Department of State, the Food and Agriculture Organization of the United Nations, and affected countries to combat the outbreak.
"APHIS is investing $109.8 million to combat new NWS detections in Central America and Mexico to keep the pest from spreading into North America," the agency's website reads.
"With this funding, APHIS aims to eradicate NWS in Central America and Mexico and re-establish the biological barrier."
On Wednesday, U.S. Agriculture Secretary Brooke Rollins said the USDA is also working with state animal health officials to draft an emergency response and stockpile medications in case NWS breaches the border, according to Reuters.
In March, infectious disease specialist Dr. Issac Bogoch took to X to spread awareness and warn Canadians, especially those travelling to destinations like the Dominican Republic, Costa Rica, and Mexico.
"The "barrier" preventing New world screwworm flies (Cochliomyia hominivorax) from spreading north of Panama has been breached," The Toronto-based doctor said on social media.
"We recently cared for a patient who contracted this infestation on a trip to Costa Rica."
Despite what its name suggests, the New World screwworm is not a worm at all—it is a species of parasitic fly.
Female screwworm flies lay their eggs in open wounds, scrapes, or insect bites on people and animals. When the eggs hatch, the larvae burrow into the flesh, feeding on living tissue and potentially causing serious wounds, infections, and even death if left untreated.
Infections occur primarily in livestock but people can and do get infected, including an 80-year-old Canadian male traveller who went to a Toronto hospital with an NWS infection (also called myiasis) after visiting Costa Rica.
Speaking with CP24, Dr. Bogoch said NWS is a public health issue that can also impact food security.
'This infection can decimate wildlife and livestock,' he told the news outlet.
NWS is commonly found in Cuba, Haiti, the Dominican Republic, and South American countries but (APHIS) says cases are spreading to Costa Rica, Nicaragua, Honduras, Guatemala, Belize, El Salvador and Mexico, beyond a biological border that had previously contained the spread.
The agency says there has been an "explosion" in NWS detections in Panama. In 2023 cases went up from an average of 25 cases annually to more than 6,500 cases in one year.
(APHIS/USDA.gov)
APHIS and Panama co-managed the biological border that "successfully" contained the pest in South America for "decades," APHIS says on its website. The now-breached barrier resides in the eastern portion of Panama.
The outbreak declarations in Costa Rica and Mexico have triggered emergency responses in the United States, Mexico, and Costa Rica, which first declared an NWS emergency in February.
According to the U.S. Centers for Disease Control and Prevention, you can become infected if:
You travel to affected areas (like Costa Rica, Nicaragua, or Mexico);
You have open cuts, sores, or scratches;
You come into contact with livestock or wildlife carrying the parasite.
Canadian travellers can protect themselves by:
Covering any cuts or scratches with clean, dry bandages;
Using insect repellent, especially on exposed skin;
Wearing long sleeves and pants in rural areas or places with plants and trees;
Avoiding close contact with stray animals or livestock;
Consulting a travel health clinic and a medical professional before travelling.
There are no vaccines or medications that prevent infection.
If you suspect infection:
Seek medical attention immediately.
Do not attempt to remove larvae yourself.
Treatment usually involves the extraction of the larvae and prescription antibiotics.
The parasite typically needs warm conditions to survive and Canada's cooler climate acts as a natural barrier.
This parasite is not currently found in Canada, but with travel-related cases increasing and the barrier that once stopped its spread now breached, Canadians heading south should be on alert.
Always check travel health advisories and when in doubt, speak to a medical professional before travel.
Header image: File photo of new age screwworm larvae (CDC].

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

How we plan to cut FDA drug approval time by months
How we plan to cut FDA drug approval time by months

Washington Post

timean hour ago

  • Washington Post

How we plan to cut FDA drug approval time by months

Marty Makary is the commissioner of the Food and Drug Administration. For more than a century, the U.S. Food and Drug Administration has been a global leader in advancing medical cures, but in recent years, its regulatory framework has become an obstacle to innovation. Cumbersome requirements, poor communication and regulatory creep have made the United States less competitive in the global race for new drugs and treatments. Meanwhile, countries such as Australia and China, with more streamlined regulations, have become go-to destinations for clinical trials and early drug testing. The shift poses a risk not just to U.S. competitiveness but also to national security. To address it, the FDA must modernize. That's why I have just announced a pilot program that can slash the FDA's drug review time from 10 to 12 months to just one to two months. The program will make use of the idle time during clinical trials — time needed to see how the drug in question performs. Instead of submitting all the data at the end of a trial, qualifying manufacturers will be able to submit most elements of the application — including manufacturing details and drug labeling — while the trial is underway. The FDA will be able to review the early data and resolve any issues with the manufacturer at that time. Once the trial concludes, final data will be submitted. Then there will be about one month of FDA review, followed by a focused, one-day meeting with FDA scientists to reach a decision. This split-submission approach is entirely feasible — as shown by its success during Operation Warp Speed at the start of the covid-19 pandemic. This novel program tackles a common pain point voiced during my national listening tour: inaccessibility of FDA reviewers for clarifying questions. Pharmaceutical CEOs repeatedly told me a simple 15-minute call with their reviewer could save months of wasted work. Our new program adopts a real-time communication model, eliminating guesswork. No more mind-reading; drug developers will get straight answers when they're needed. As a surgical oncologist, I've experienced firsthand the benefits of team-based decision-making as a participant in 'tumor board' meetings where specialists collaborate to make critical decisions. A similar team approach can be applied at the FDA to evaluate the safety and efficacy of new drugs. In my first 12 weeks leading the FDA, we've made significant strides toward modernizing the agency. One example is the launch of Elsa, a tool powered by artificial intelligence that helps FDA reviewers sift through thousands of pages of data in minutes, instead of days. This tool is already being used by thousands of FDA staff daily, enabling them to focus more on what matters most: scientific expertise. Elsa doesn't replace human judgment but accelerates the review process, making the FDA more efficient and responsive. We're also speeding up approvals by phasing out outdated animal testing, replacing it with cutting-edge tools such as computational modeling and organ-on-a-chip toxicity testing, where a miniaturized, three-dimensional tissue mimics human function. These techniques are faster, cheaper and better at predicting human toxicity. Notably, about 90 percent of drugs that pass animal studies fail in humans. The FDA has even required animal studies on drugs already approved in Europe. We need both gold-standard science and common sense. Newer methods can be more predictive and humane. For drug developers, time is money. A previous valuable priority review program for rare pediatric diseases shortened FDA review time from 10 to 12 months to six. The market value of the six-month review was approximately $100 million to the pharmaceutical companies, showing that faster approval processes can be highly valuable. A one-month review process could be significantly more valuable and could incentivize companies to act on national priorities. These could include boosting domestic manufacturing for national security, addressing unmet public health needs or developing products for pandemic preparedness. The new national priority review program is designed to align speed, science and strategy. It rewards companies working on innovative solutions to real challenges faced by the American public, without sacrificing safety or the FDA's rigorous standards. By modernizing the FDA, we can ensure that the future of medicine is written in the United States. .

Cardinal Health, Inc. (CAH) CEO Is 'Terrific,' Says Jim Cramer
Cardinal Health, Inc. (CAH) CEO Is 'Terrific,' Says Jim Cramer

Yahoo

time2 hours ago

  • Yahoo

Cardinal Health, Inc. (CAH) CEO Is 'Terrific,' Says Jim Cramer

Cardinal Health, Inc. (NYSE:CAH) is one of the . Cardinal Health, Inc. (NYSE:CAH) is one of the biggest healthcare products and services providers in America. The shares are up by 36% year-to-date as they have benefited from strong earnings and other tailwinds. Cramer has discussed Cardinal Health, Inc. (NYSE:CAH) several times in 2025. He believes that the firm's specialty pharma business is a key differentiating factor and added that it could benefit if the Trump Administration decides to shake things up in the pharmaceutical supply chain. Here are his latest thoughts about Cardinal Health, Inc. (NYSE:CAH): 'Okay, you know I got a company, I mentioned it yesterday, Cardinal Health. These, it's not a middleman. Everyone thinks it's just a middleman. Jason Hollar's carving out a real place to make healthcare, let's say better, streamlined, and cheaper. I just think this guy's terrific, and I'm happy to have him on the show. He's not a villain.' Cramer discussed Cardinal Health, Inc. (NYSE:CAH) in detail in May. Here is what he said: 'These stocks. . .are seemingly perpetual residents on the new high list. Over the long haul, they're some of the best performers out there, and they've done great this year, as is pretty much always the case. And yet, doesn't it always feel like the drug distributors are just one bad day away from falling apart… Let's not forget that the drug distributors are making fortunes right now. Cardinal Health turned in an excellent set of numbers two weeks ago with double-digit earnings growth. Management put through a big boost in their full-year earnings forecast. Cardinal stock jumped 3% in response, climbing from $141 to $145, and it kept running for really a week after that, eventually setting at an all-time high of $154 just last Thursday. What a fabulous move… A senior physician in a modern healthcare institution administering medication to a patient. Now, if you really want to own one, and I do like this one, Cardinal Health is the one to do it with because it provides a lot more value-added services than the others. Now, we've had Cardinal on several times, and I think they're doing some very innovative things. They are impressive, they're beyond middlemen.' While we acknowledge the potential of CAH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store